Stellus Capital Investment Corp. 10-Q Summary (Period Ended June 30, 2019)
Business Context and Reporting Period
Stellus Capital Investment Corp. (SCM) is an externally managed, closed-end, non-diversified business development company (BDC) regulated under the Investment Company Act of 1940. The company invests primarily in debt and related equity securities of middle-market U.S. companies. This report covers the quarterly period ended June 30, 2019, and the six-month period ended June 30, 2019, compared to the same periods in 2018.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 |
|---|---|---|
| Total Investment Income | $28.0 million | $23.5 million |
| Net Investment Income | $9.7 million ($0.55 per share) | $9.2 million ($0.58 per share) |
| Net Realized Gains | $12.9 million | $2.4 million |
| Net Unrealized Depreciation | ($6.5 million) | $3.4 million (Appreciation) |
| Net Increase in Net Assets from Operations | $16.1 million ($0.92 per share) | $14.9 million ($0.94 per share) |
| Total Assets | $553.2 million | $526.3 million (Dec 31, 2018) |
| Net Assets | $270.1 million | $224.8 million (Dec 31, 2018) |
| Net Asset Value (NAV) Per Share | $14.29 | $14.09 (Dec 31, 2018) |
| Cash and Cash Equivalents | $18.2 million | $17.5 million (Dec 31, 2018) |
| Total Debt Outstanding | $276.2 million | $296.3 million (Dec 31, 2018) |
| Asset Coverage Ratio | 312% | 251% (Dec 31, 2018) |
Note: Total Debt includes Notes Payable ($47.8M), Credit Facility ($77.7M), and SBA-guaranteed debentures ($146.7M).
Material Changes vs. Prior Period
- Portfolio Growth: The investment portfolio grew from $504.5 million (fair value) at year-end 2018 to $531.1 million at June 30, 2019. This was driven by $78.1 million in new investments and $58.8 million in proceeds from repayments.
- Realized Gains: Net realized gains increased significantly to $12.9 million for the six months ended June 30, 2019, compared to $2.4 million in the prior year period. This was primarily due to realizations of equity investments and payments from a previously impaired portfolio company.
- Unrealized Depreciation: The company recorded a net unrealized depreciation of $6.5 million for the six months ended June 30, 2019, contrasting with $3.4 million of appreciation in the prior year. This shift was attributed to company-specific performance and accounting reversals related to realized gains, partially offset by tightening credit spreads.
- Equity Offering: The company completed a secondary offering in the first half of 2019, issuing approximately 2.95 million shares for gross proceeds of $42.6 million, increasing net assets significantly.
- Debt Reduction: The company reduced its Credit Facility balance from $99.6 million at year-end 2018 to $78.8 million at June 30, 2019, while maintaining $150.0 million in SBA-guaranteed debentures.
Guidance, Outlook, and Risks
- Outlook: Management continues to seek to maximize total return through debt and equity investments in middle-market companies. The company maintains sufficient liquidity to fund unfunded commitments of $18.6 million.
- Dividends: The company declared a regular monthly dividend of $0.1133 per share for July, August, and September 2019. Distributions are generally paid monthly.
- Asset Coverage: The company operates under a modified asset coverage requirement of 150% (reduced from 200% in June 2018). As of June 30, 2019, the ratio was 312%, providing significant leverage capacity.
- Risks:
- Non-Accrual Status: Four loans were on non-accrual status as of June 30, 2019, representing 6.1% of the loan portfolio at cost. Specific investments (e.g., Refac Optical Group, Wise Holding Corporation) are noted as past due or on non-accrual.
- Interest Rate Sensitivity: 91% of the debt portfolio bears floating interest rates. A 100 basis point increase in rates would increase net income by approximately $3.7 million annually, while a decrease would reduce it by a similar amount.
- Concentration: The portfolio is concentrated in Business Services (16.7%) and Healthcare & Pharmaceuticals (15.0%).
Investor Verification Checklist
- Non-Accrual Loans: Verify the status and potential recovery value of the four loans on non-accrual status, specifically Refac Optical Group and Wise Holding Corporation.
- Unrealized Depreciation: Review the specific portfolio companies driving the $6.5 million unrealized depreciation to assess if these are temporary market fluctuations or fundamental credit deterioration.
- Capital Gains Incentive Fee: Note the accrual of $1.3 million in capital gains incentive fees, which may not be payable until realized gains are confirmed in future periods.
- Unfunded Commitments: Confirm the company's ability to fund the $18.6 million in unfunded commitments given current cash levels and credit facility availability.
- Dividend Coverage: Monitor the ratio of Net Investment Income to distributions to ensure the company can maintain its $0.1133 monthly dividend without returning capital.